Professional
Added to YB: 2025-11-25
Pitch date: 2025-11-23
ABVX [bullish]
ABIVAX Société Anonyme
+4.44%
current return
Author Info
No bio for this author
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 7.8B
Pitch Price
EUR 103.60
Price Target
175.00 (+62%)
Dividend
N/A
EV/EBITDA
-42.16
P/E
-33.24
EV/Sales
1.3K
Sector
Biotechnology
Category
special_situation
Is Intralinks the Tell-Tale Sign Abivax Is in Active/Advance Stage M&A Negotiations? I think so: expecting rerating & still juicy premium.
ABVX: Late-stage biotech w/ obefazimod for ulcerative colitis showing best-in-class efficacy. Author found active Intralinks data room suggesting advanced M&A talks. Barclays sees 60% takeover premium (~$150/share). 3x peak sales multiple on $4.5B revenue = $175 target (56% upside). CEO has quick exit track record.
Read full article (7 min)